ClinicalTrials.gg
Status unknownNCT01550419Updated Feb 26, 2013

Effect of Atorvastatin on the Frequency of Ventilator-associated Pneumonia in Patients With Ischemic Stroke

An Early Phase 1 interventional study of Atorvastatin and Placebo in Ventilator-associated Pneumonia and Ischemic Stroke, sponsored by Shanghai Minhang Central Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-02-26.

Sponsored by Shanghai Minhang Central Hospital · Early Phase 1, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Feb 2013), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Pneumonia, Ventilator-Associated with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Pneumonia, Ventilator-Associated · China.

Planned enrollment
10th of 17
100 · median 174
Started
2012
the only one that year
Phase 1
Only one
of the 26
Registered
2nd of 26
by date
Lead sponsor
2 of 26
Shanghai Minhang Central Hospital

Among the 26 studies in Pneumonia, Ventilator-Associated with a site in China, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2012, is the only one in phase 1, and was the 2nd registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

10 of the 26 studies in Pneumonia, Ventilator-Associated with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pneumonia, Ventilator-Associated with a site in China, or all of them as a file.
02

Study summary

Ventilator-associated pneumonia (VAP) is an important cause of morbidity and mortality in ventilated critically ill patients specially in intensive care unit (ICU). It is associated with an increased duration of mechanical ventilation, high death rates and increased healthcare costs in China. However, VAP is preventable and many practices have been demonstrated to reduce the incidence of this disease, but the morbidity is still so high. So much more methods of prevention should be needed to reduce the incidence of VAP.

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) present anti-inflammatory and immunomodulatory effects besides their ability to regulate cholesterol composition. So it is hypothesized that early use of statin may prevent some of the infection disease such as VAP.

Actually, Two studies have showed that statin treatment is associated with reduced risk of pneumonia. However, the relationship between statins and reduced risk of pneumonia is not consistent.

After reviewing some of the guidelines,meta analyses and system reviews, the investigator find that advanced age,immune suppression from disease or medication and specially depressed level of consciousness are the risk factors of VAP. So the investigator assumes that early use of statin may give us a favorable outcome in the patients with coma or in the patients with severe disease (Acute Physiology and Chronic Health Evaluation II score > 15 or Glasgow coma score \< 7).

In addition there is no prospective study to investigate the role of statins in VAP in the patients with ischemic stroke. The investigator hopes that this study can approve the relationship between statins and reduced risk of VAP in the patients with ischemic stroke. And it can improve the processes,outcomes and costs of critical care as well.

Read the detailed description

This is a one-center, two-arm, randomized, single-blinded, controlled trial. When a patient with ischemic stroke who needs mechanic ventilation is admitted to ICU,a sealed envelop will be opened which decide whether the patient is assigned to the placebo arm or the atorvastatin arm. During they stay in ICU, one tablet of atorvastatin (40mg) or one tablet of placebo will be administered. Atorvastatin or placebo will be administered through an enteral feeding tube or administered orally when patients are able to safely take oral medications.

VAP diagnosis accords with the comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia:Diagnosis and treatment which was published in 2008.

03

Conditions studied

  • Ventilator-associated Pneumonia
  • Ischemic Stroke

Keywords

  • Ventilator-associated pneumonia
  • Ischemic stroke
  • Atorvastatin
  • Morbidity
  • Mortality
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All consecutive patients with ischemic stroke who are admitted to Intensive Care Unit(ICU) between 1st March.2012 at 00:00 hours (midnight) and the finish date of 31st March. 2014 at 23:59 hours (11.59 pm). Patients who are already in the ICU prior to 1st March. 2012 at 00:00 hours will not be included in the study.
  • Duration of mechanical ventilation > 48h through tracheal tube or tracheotomy

Exclusion criteria

Exclusion Criteria:

  • Patients with pneumonia when they are admitted to ICU.
  • Previous use of statin for cholesterol regulation.
  • Chronic liver disease or active liver disease.
  • Increase of CPK (over 3 times the upper limit) during hospitalization.
  • Malnutrition.
  • Pregnancy.
  • Unwilling to continue the therapy during hospitalization.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Atorvastatin(50 characters)

    Drug: Atorvastatin

  • Placebo comparator
    Placebo(50 characters)

    Drug: Placebo

Interventions

  • Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.

    Also known as: Lipitor

  • DrugPlacebo

    The smell and shape of placebo are the same as atorvastatin

    Also known as: No other name

06

What researchers measure

Primary outcomes

  1. Cumulative frequency of ventilator-associated pneumonia

    Time frame: 30 days

Secondary outcomes

  1. Mortality

    Time frame: 30 days

  2. Ventilation free days

    Time frame: 30 days

  3. Antibiotic free days

    Time frame: 30 days

  4. Whether the bacteria of multidrug-resistance can be isolated from the sputum culture

    We will find whether methicillin-resistant Staphylococcus aureus(MRSA), extended-spectrum beta-lactamase(ESBLs) or Vancomycin-resistant enterococcus (VRE)can be isolated from the sputum culture.

    Time frame: 30 days

  5. Adverse effects

    Creatine kinase of more than three times the upper normal limit or hepatic enzyme dysfunction.

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
  • Shanghai Minhang Central Hospital
    Shanghai, 201199, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2012
First posted
Mar 12, 2012
Start
Mar 2012
Primary completionEst.
Feb 2014
CompletionEst.
Feb 2014
Last update
Feb 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01550419
Lead sponsor
Shanghai Minhang Central Hospital
Responsible party
Liu Chunyan (Department of Intensive Care Unit, Minhang Central Hospital, Shanghai Minhang Central Hospital) — Principal investigator
First posted
Mar 12, 2012
Start date
Mar 2012
Primary completion
Feb 2014 (estimated)
Completion
Feb 2014 (estimated)
Last update
Feb 26, 2013

Study contacts

Liu ChunYan, MD
Contact
doctorlcy@sina.com
021-64923400
Yu YueTian, MD
Contact
fishyyt@sina.com
021-64923400
Liu ChunYan, MD
principal investigator · Shanghai Minhang Central Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion